TOPIC:

Eli Lilly

Watch breaking news videos and read news updates about Eli Lilly on FOXBusiness.com.

LATEST VIDEOS

Tips for Investors

11/05/2009|FOX Business

Tips for InvestorsMarket Experts Jim Lowell and Charles Robinson on where to invest today.

Housing Sales Dependent on Tax Credit?

09/17/2009|Happy Hour on FOX Business

Housing Sales Dependent on Tax Credit?Real estate broker Connie DeGroot on whether the first time home-buyers credit is essential.

Eli Lilly CEO: Layoffs are Last Resort

09/14/2009|FOX Business

Eli Lilly CEO: Layoffs are Last ResortEli Lilly CEO John Lechleiter on the pharmaceutical company's 5,500 job costs.

Pfizer Offers Free Drugs to Jobless

05/14/2009|Closing Bell

Pfizer Offers Free Drugs to JoblessDr. Jorge Puente, regional president of worldwide pharmaceuticals at Pfizer, on the company's program for distributing medication to the unemployed.

Lilly CEO Sounds Off on Health-Care Funding

05/14/2009|FOX Business

Lilly CEO Sounds Off on Health-Care FundingExclusive: Eli Lilly CEO John Lechleiter on government proposed health care reform, funding for biomedical innovations, and what it will mean to the industry.

Lilly CEO: On Verge of Scientific Advance

05/14/2009|FOX Business

Lilly CEO: On Verge of Scientific AdvanceExclusive: Eli Lilly CEO John Lechleiter on government proposed health care reform, funding for biomedical innovations, and what it will mean to the industry.

Vanda Shares Surge on Drug Approval

05/08/2009|Closing Bell

Vanda Shares Surge on Drug ApprovalPolymeropoulos on Fanapt

Challenges facing Pharmaceutical Sector

02/03/2009|Money for Breakfast

Challenges facing Pharmaceutical SectorWhat are the challenges for pharmaceuticals?

Bristol-Myers & Exelixis Join Forces

12/12/2008|FOX Business Morning

Bristol-Myers & Exelixis Join ForcesBristol-Myers and Exelixis collaboration.

LATEST STORIES

Vivus Reports Postive Study Results For ED Drug

By By Val Brickates Kennedy| MarketWatch Pulse| Markets

avanafil can effectively compete in the oral ED therapy market," Wilson added. Other PDE5 inhibitors for ED include Eli Lilly & Co.'s Cialis, Pfizer Inc.'s Viagra, and GlaxoSmithKline plc's Levitra. Copyright © 2009 MarketWatch, Inc

Story|11/18/2009

Eli Lilly Adds New Head of Research

By By Darryl R. Isherwood| FOXBusiness| Markets

By Darryl R. Isherwood FOXBusiness Eli Lilly and Co. (LLY) has poached Jan Lundberg, AstraZeneca Plc ..... from stable to negative to reflect “uncertainty of Eli Lilly ’s ability to counter its exposure to key drug patent

Story|11/13/2009

Fitch Cuts Its Outlook On Eli Lilly To Negative

By By MarketWatch| MarketWatch Pulse| Markets

Fitch Ratings has changed its rating outlook Friday on Eli Lilly & Co. to negative from stable, which applies to about ..... debt. Fitch said the move reflects its "uncertainty of Eli Lilly 's ability to counter its exposure to key drug patent

Story|11/13/2009

Mixed Results For Amgen’s Latest Vectibix Trial

FOXBusiness| Markets

approximately 40% of colon cancer patients. Vectibix’s main competitor in the space is Erbitux, which is sold by Eli Lilly (LLY) and Bristol-Myers Squibb (BMY). Last year, Erbitux sales rose 8% to $739 million, while Vectibix sales

Story|11/05/2009

Laying on Bets at America's Biggest Pension Fund

Reuters| Markets

corporate governance laggards with a Focus List that commands considerable attention. Targets have ranged from drug company Eli Lilly & Co to chairmaker La-Z-Boy. Calpers argues that singling out corporate inadequacies leads to better stock performance

Story|10/23/2009

GE and Lilly Announce Cancer Breakthrough

By Darryl R. Isherwood| FOXBusiness| Markets

Darryl R. Isherwood FOXBusiness Scientists at GE Global Research, part of General Electric (GE), and Eli Lilly and Co. (LLY) announced an advancement in cancer research that is a result of the partnership formed in 2007 between the two

Story|10/21/2009

Eli Lilly Beats the Street on Volume Gains

FOXBusiness| Markets

FOXBusiness Pharmaceutical company Eli Lilly & Co. (LLY) swung to a profit for its third quarter, a year after getting stung by lawsuits related to its anti-psychotic

Story|10/21/2009

Eli Lilly Swings To Profit, Boosts Guidance

By William L. Watts| MarketWatch Pulse| Markets

William L. Watts MarketWatch Pulse LONDON -- Eli Lilly and Co. on Wednesday said it swung to a third quarter profit of $941.8 billion, or 86 cents a share, from a loss of $465

Story|10/21/2009

Bove Triggers Late Dive on Wall Street

By Ken Sweet| FOXBusiness| Markets

competitor Goldman Sachs (GS). The pharmaceutical sector will also be in focus today with results out of Amgen (AMGN), Eli Lilly (LLY) and Genzeme (GENZ). In early trading, oil was down more than 1.15% to $78.20 a barrel while gold fell

Story|10/21/2009

Stocks In Focus For Wednesday

By MarketWatch| MarketWatch| Markets

projected to post a third-quarter profit of 37 cents a share, according to analysts surveyed by FactSet Research. Eli Lilly and Co. (LLY) is likely to report a third-quarter profit of $1.02 a share, according to analysts surveyed by

Story|10/20/2009

«12345»